Iteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.
Although it has only been shown to provide partial protection, the first-ever malaria vaccine is in testing in Africa – and there are many more hopefuls in the pipeline. Will we soon eradicate one of the most deadly pathogens in human history?
The FDA has given the go-ahead to PharmaMars proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.
Manufacturers respond to stricter regulations with novel approaches.
Researchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts.
British researchers have found out what’s going wrong with chromosome segregation in some cancers.
Pharming NV has paid €17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS
Researchers have discovered that crosstalk of a newly discovered stem cell population with quiescent stem cells may help repair teeth in the future.
Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics.
Using a platform tailored to patients specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.